Status:
UNKNOWN
Comparison of Vitrification Effect Before or After In Vitro Maturation
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborating Sponsors:
Origio A/S
Conditions:
Oocytes Vitrified at Prophase-I Stage
Oocytes Matured in Vitro
Eligibility:
FEMALE
18-37 years
Brief Summary
Human oocyte cryopreservation is routinely used for fertility preservation of women who will be exposed to gonadotoxic effect of cancer treatment. After ovarian stimulation, matured oocytes are vitrif...
Detailed Description
Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from...
Eligibility Criteria
Inclusion
- \- ICSI treatment
- Immature oocytes
- \< 37 years old
Exclusion
- \- Polyckistic Ovarian Syndrome
- Endometriosis
- Ovulatory disease
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03416400
Start Date
January 1 2017
End Date
December 31 2019
Last Update
February 1 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003